HanchorBio, led by Chairman Dr. Scott Liu, is breaking barriers in tumor immunotherapy! With its B-round funding secured in 2024, the company is set to advance HCB101 into Phase 1b/2a clinical trials in Q1 2025, targeting five types of cancer. 
Why HCB101 is a Game-Changer?

• Next-gen immunotherapy tackling solid tumors 
• Early clinical trials show promising safety & efficacy 
• IPO planned for 2025 to accelerate global expansion 

With cancer treatment innovation at its core, HanchorBio is set to make waves in the biotech world! 
Read more: http://bit.ly/v123industry
Follow #Globalbio for the latest in biotech breakthroughs! 
#BiotechRevolution #CancerTherapy #Immunotherapy #HanchorBio #ClinicalTrials #BiotechIPO #NextGenMedicine #Globalbio
https://www.linkedin.com/company/hanchorbio-inc/